This summary was created by AI, based on 1 opinions in the last 12 months.
Experts believe that Cassava Sciences (SAVA-Q) has the potential to triple its shares if they produce a major drug, but there is also a risk of shares drifting down if they fail to do so. Overall, the risk/reward ratio is seen as favorable by the experts, making it an intriguing investment opportunity. However, there are concerns about the outcome of the company's drug development efforts, which could significantly impact the stock's performance in the future.
It loses a lot of money. Can't recommend any of those companies.
Cassava Sciences is a American stock, trading under the symbol SAVA-Q on the NASDAQ (SAVA). It is usually referred to as NASDAQ:SAVA or SAVA-Q
In the last year, 1 stock analyst published opinions about SAVA-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Cassava Sciences.
Cassava Sciences was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Cassava Sciences.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Cassava Sciences published on Stockchase.
On 2024-12-11, Cassava Sciences (SAVA-Q) stock closed at a price of $2.85.
If they produce a big drug, shares can triple, but if they don't, then shares drift down. He likes the risk/reward ratio.